The estimated Net Worth of Frederick G Vogt is at least $4.01 Million dollars as of 3 September 2024. Frederick Vogt owns over 57,292 units of Iovance Biotherapeutics Inc stock worth over $1,983,836 and over the last 7 years he sold IOVA stock worth over $0. In addition, he makes $2,025,180 as General Counsel and Corporate Secretary at Iovance Biotherapeutics Inc.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Sign up
Frederick Vogt IOVA stock SEC Form 4 insiders trading
Frederick has made over 12 trades of the Iovance Biotherapeutics Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently he exercised 57,292 units of IOVA stock worth $535,680 on 3 September 2024.
The largest trade he's ever made was exercising 83,325 units of Iovance Biotherapeutics Inc stock on 17 January 2023 worth over $779,089. On average, Frederick trades about 15,985 units every 41 days since 2017. As of 3 September 2024 he still owns at least 212,175 units of Iovance Biotherapeutics Inc stock.
You can see the complete history of Frederick Vogt stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Frederick Vogt biography
Dr. Frederick G. Vogt Ph.D. Esq. serves as General Counsel, Corporate Secretary of the Company. Dr. Vogt joined the Company on September 30, 2016 as our Vice President, Intellectual Property. Dr. Vogt was promoted to General Counsel on July 1, 2017. From May 2013 until he joined the Company, Dr. Vogt practiced law at the international law firm of Morgan, Lewis & Bockius LLP, focusing on intellectual property and business law in the life sciences and representing clients in patent strategy, transactional, and litigation matters. Prior to joining Morgan, Lewis & Bockius LLP, he served in numerous scientific, management, and legal roles of increasing responsibility over a period of 13 years at GlaxoSmithKline plc., where he focused primarily on oncology and cardiovascular drug development. Dr. Vogt holds a B.S. in Chemistry from Ursinus College, a Ph.D. in Chemistry from the Pennsylvania State University, and a J.D. from Temple University. He is admitted to practice in Pennsylvania and before the U.S. Patent and Trademark Office and the U.S. District Court for the Eastern District of Pennsylvania.
What is the salary of Frederick Vogt?
As the General Counsel and Corporate Secretary of Iovance Biotherapeutics Inc, the total compensation of Frederick Vogt at Iovance Biotherapeutics Inc is $2,025,180. There are 2 executives at Iovance Biotherapeutics Inc getting paid more, with Maria Fardis having the highest compensation of $4,107,960.
How old is Frederick Vogt?
Frederick Vogt is 46, he's been the General Counsel and Corporate Secretary of Iovance Biotherapeutics Inc since 2019. There are 14 older and no younger executives at Iovance Biotherapeutics Inc. The oldest executive at Iovance Biotherapeutics Inc is Merrill McPeak, 84, who is the Independent Director.
What's Frederick Vogt's mailing address?
Frederick's mailing address filed with the SEC is C/O IOVANCE BIOTHERAPEUTICS, INC., 825 INDUSTRIAL ROAD, 4TH FLOOR, SAN CARLOS, CA, 94070.
Insiders trading at Iovance Biotherapeutics Inc
Over the last 8 years, insiders at Iovance Biotherapeutics Inc have traded over $0 worth of Iovance Biotherapeutics Inc stock and bought 22,614,553 units worth $159,655,586 . The most active insiders traders include Wayne P. Rothbaum, Merrill A Mcpeak, and Timothy E Morris. On average, Iovance Biotherapeutics Inc executives and independent directors trade stock every 37 days with the average trade being worth of $3,815,146. The most recent stock trade was executed by Frederick G Vogt on 3 September 2024, trading 57,292 units of IOVA stock currently worth $535,680.
What does Iovance Biotherapeutics Inc do?
iovance biotherapeutics is focused on the development and commercialization of novel cancer immunotherapies based on tumor infiltrating lymphocytes (til). this approach, also known as adoptive t-cell therapy, was initially developed by dr. steven a. rosenberg at the national cancer institute (nci). in phase 2 clinical trials conducted at the nci, 56% and 24% of patients treated with this technology were reported by nci to have achieved objective and complete response criteria, respectively. our lead product candidate is an autologous, ready-to-infuse cell therapy, that has demonstrated distinctive efficacy in the treatment of metastatic melanoma. in addition to metastatic melanoma, carcinoma of the head and neck and cervical cancer our til therapy technology is potentially applicable to many other tumor types, including ovarian, breast, bladder, colorectal and other cancers. as we continue advancing our current clinical programs through the introduction of manufacturing and logistical
What does Iovance Biotherapeutics Inc's logo look like?
Complete history of Frederick Vogt stock trades at Iovance Biotherapeutics Inc
Iovance Biotherapeutics Inc executives and stock owners
Iovance Biotherapeutics Inc executives and other stock owners filed with the SEC include:
-
Maria Fardis,
President, Chief Executive Officer and Director -
Friedrich Graf Finckenstein,
Chief Medical Officer -
Frederick Vogt,
General Counsel, Corporate Secretary -
Iain Dukes,
Chairman of the Board -
Michael Weiser,
Independent Director -
Jean-Marc Bellemin M.B.A.,
Chief Financial Officer & Principal Accounting Officer -
Dr. Friedrich Graf Finckenstein M.D.,
Chief Medical Officer -
Dr. Frederick G. Vogt Esq., J.D., Ph.D.,
Interim Pres, CEO, Gen. Counsel & Corp. Sec. -
Merrill McPeak,
Independent Director -
Ryan Maynard,
Independent Director -
Athena Countouriotis,
Director -
Michael Swartzburg,
Interim Principal Financial Officer and Principal Accounting Officer -
Sara Pellegrino,
IR Contact Officer -
Wayne Rothbaum,
Independent Director -
Dr. Elma S. Hawkins,
Advisor to the Board -
Madan Jagasia,
Sr. VP of Medical Affairs -
James Ziegler,
Sr. VP of Commercial -
Howard B. Johnson,
Sr. VP of Corp. Devel., Alliance Management & Program Management -
Dr. Igor P. Bilinsky,
Chief Operating Officer -
Timothy E Morris,
Chief Financial Officer -
Jean Marc Bellemin,
Chief Financial Officer -
Igor Bilinsky,
Chief Operating Officer -
Wendy L Yarno,
Director -
Wendy L Dixon,
Director